Novo Nordisk Q2 2024 Earnings Highlights
Novo Nordisk delivered exceptional performance in the first half of 2024, with sales growing 25% and ...
Read moreNovo Nordisk delivered exceptional performance in the first half of 2024, with sales growing 25% and ...
Read moreNovo Nordisk's Ozempic has shown promising ancillary benefits beyond its primary use for diabetes and weight ...
Read moreSenator Bernie Sanders expressed confidence that Novo Nordisk can be pressured to reduce the U.S. prices ...
Read moreNovo Nordisk shares fell 1.1% on Tuesday following a JAMA Internal Medicine analysis showing Eli Lilly’s ...
Read moreNovo Nordisk shares dropped nearly 4%, and Eli Lilly saw a more than 1% decline after ...
Read more© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy. Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability. Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet. Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides. Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services. Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018
© 2024 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy. Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability. Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet. Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides. Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services. Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018